Rhenman & Partners Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-580,000
| Closed | -$16.7M | – | 93 |
|
|
2023
Q4 | $16.7M | Buy |
+580,000
| New | +$17.5M | 1.67% | 21 |
|
|
2023
Q2 | – | Sell |
-190,000
| Closed | -$7.67M | – | 88 |
|
|
2023
Q1 | $7.67M | Sell |
190,000
-160,000
| -46% | -$6.91M | 0.84% | 39 |
|
|
2022
Q4 | $17.9M | Hold |
350,000
| – | – | 1.87% | 20 |
|
|
2022
Q3 | $16.3M | Sell |
350,000
-190,000
| -35% | -$9.23M | 1.71% | 22 |
|
|
2022
Q2 | $28.3M | Buy |
540,000
+17,500
| +3% | +$892K | 3.22% | 5 |
|
|
2022
Q1 | $27.1M | Sell |
522,500
-477,500
| -48% | -$24.8M | 2.67% | 7 |
|
|
2021
Q4 | $58.4M | Hold |
1,000,000
| – | – | 3.88% | 2 |
|
|
2021
Q3 | $43M | Buy |
1,000,000
+500,000
| +100% | +$22.2M | 3.02% | 5 |
|
|
2021
Q2 | $19.6M | Buy |
+500,000
| New | +$19.4M | 1.33% | 32 |
|
|
2020
Q3 | – | Sell |
-4,751
| Closed | -$147K | – | 91 |
|
|
2020
Q2 | $147K | Buy |
+4,751
| New | +$161K | 0.02% | 90 |
|
|
2019
Q2 | – | Sell |
-5,279
| Closed | -$213K | – | 93 |
|
|
2019
Q1 | $213K | Hold |
5,279
| – | – | 0.02% | 91 |
|
|
2018
Q4 | $219K | Sell |
5,279
-3,948
| -43% | -$164K | 0.03% | 88 |
|
|
2018
Q3 | $386K | Hold |
9,227
| – | – | 0.04% | 78 |
|
|
2018
Q2 | $318K | Hold |
9,227
| – | – | 0.03% | 86 |
|
|
2018
Q1 | $311K | Sell |
9,227
-1,758
| -16% | -$60.4K | 0.04% | 90 |
|
|
2017
Q4 | $377K | Hold |
10,985
| – | – | 0.05% | 90 |
|
|
2017
Q3 | $372K | Sell |
10,985
-442,680
| -98% | -$14.2M | 0.05% | 88 |
|
|
2017
Q2 | $14.5M | Buy |
453,665
+100,130
| +28% | +$3.16M | 2.08% | 14 |
|
|
2017
Q1 | $11.5M | Buy |
353,535
+2,237
| +0.6% | +$70.5K | 1.82% | 18 |
|
|
2016
Q4 | $10.8M | Buy |
+351,298
| New | +$10.7M | 2.08% | 15 |
|
|
2016
Q3 | – | Sell |
-395,250
| Closed | -$13.2M | – | 115 |
|
|
2016
Q2 | $13.2M | Sell |
395,250
-105,400
| -21% | -$3.36M | 2.34% | 8 |
|
|
2016
Q1 | $14.1M | Buy |
500,650
+38,998
| +8% | +$1.11M | 2.79% | 4 |
|
|
2015
Q4 | $14.1M | Buy |
461,652
+17,918
| +4% | +$564K | 2.14% | 9 |
|
|
2015
Q3 | $13.2M | Buy |
+443,734
| New | +$14.2M | 2.11% | 14 |
|
|
2014
Q2 | – | Sell |
-372,050
| Closed | -$11.3M | – | 104 |
|
|
2014
Q1 | $11.3M | Buy |
+372,050
| New | +$11.1M | 3.4% | 5 |
|
Other funds holding PFE
Rhenman & Partners Asset Management's PFE Position: Q1 2024 in Review
Rhenman & Partners Asset Management sold out of Pfizer (PFE) in Q1 2024, closing a stake of 580,000 shares — an estimated $16.7M sold.
Rhenman & Partners Asset Management first reported a position in PFE in Q1 2014 and held it in 25 quarters. The position peaked at $58.4M in Q4 2021. 2,875 funds tracked by Wall St. Rank hold PFE as of Q1 2024.
- Rhenman & Partners Asset Management reported no remaining Pfizer position as of Q1 2024 after selling out during the quarter.
- Rhenman & Partners Asset Management sold 580,000 Pfizer shares in Q1 2024, an estimated $16.7M.
- Rhenman & Partners Asset Management first reported a position in Pfizer in Q1 2014 and held it in 25 quarters.
- Rhenman & Partners Asset Management's Pfizer position peaked at $58.4M in Q4 2021.
- 2,875 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.
Based on Rhenman & Partners Asset Management's 13F filing for Q1 2024, filed 14 May 2024.